Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003:(287):53-62.

[Assessment of nonpenetrating deep sclerectomy with reticulated hyaluronic acid implant SKGEL and/or preoperative application of 5-luorouracil: results of 2 and a half years]

[Article in French]
Affiliations
  • PMID: 12784578

[Assessment of nonpenetrating deep sclerectomy with reticulated hyaluronic acid implant SKGEL and/or preoperative application of 5-luorouracil: results of 2 and a half years]

[Article in French]
M Detry-Morel et al. Bull Soc Belge Ophtalmol. 2003.

Abstract

Purpose: To assess the effectiveness and the safety of deep sclerectomy (DS) with reticulated hyaluronic acid implant (SKGEL) and/or 5-Fluorouracile (5-FU).

Material-methods: 42 phakic eyes (42 patients) (mean age: 61.0 +/- 11.5 years) with medically uncontrolled open angle glaucoma and without history of previous filtering procedure were included in this non-randomized retrospective study. According to the peroperative protocol, the patients were categorized into 3 groups: DS + SKGEL (7 eyes), DS + 5-FU (50/mg/ml during 3 minutes) (13 eyes) and group C with SKGEL and 5-FU simultaneously (22 eyes).

Results: The mean follow up was 30.6 +/- 9.2 months and was significantly shorter in group C. The 3 groups were comparable with respect to the age of the patients, the severity of glaucomatous defects, the distribution of the target IOP, the mean number and duration of preoperative medications as well as to the mean preoperative visual acuity and IOP. The mean IOP was significantly decreased from 27.3 +/- 3.2 mm Hg to 16.1 +/- 3.7 3.7 mm Hg (p < 0.0001) and was not significantly different between the 3 groups at 24 months follow up (p > 0.05). Mean visual acuity was not significantly altered in the 3 groups (p > 0.05). Complete (target IOP reached without medication or YAG laser goniopuncture) and qualified (target IOP reached with medication and/or YAG laser goniopuncture) final success rates were respectively 33.3% and 83.3%. The frequency of distribution of success was not significantly different between the 3 groups but the percentage of success was 100% in group A, 84.6% in group B and 77.2% in group C. Subconjunctival injections were needed in 33% in the first postoperative month. (group A: 28.5%; group B: 46.2%; group C: 27.2%) (X2 p > 0.05). Postoperative complications were relatively minor and were observed in 66% (P > 0.05 between the 3 groups). YAG laser goniopunctures were performed in 38% (group A: 16.6%; group B: 61.5%; group: 33.3%, X2 p > 0.05). Complete and qualified success probability were better in SKGEL group comparatively with the other 2 groups.

Conclusions: Considering its limitations and with a follow-up of 2 years and half, this study could confirm the safety and the efficacy of DS in return for which topical medication(s) and/or YAG laser gonioperforations were needed in a relatively high percentage of the cases. The benefits of the SKGEL implant on the quality of the IOP control appeared to be higher than 5-FU.

PubMed Disclaimer

Similar articles

Publication types